She has served as an instructor to the Rural Underserved Opportunity Program (RUOP) since 1990, and a Clinical Assistant Professor of Family Medicine for the University of Washington Department of Family Medicine. Luke’s Wood River Family Medicine where she has practiced since 1988. Her long span of service to this medically underserved rural Idaho community is just one part of her career-long commitment to rural healthcare. has served as the Assistant Medical Director of the Challis Area Health Center since 1999. Kathy Woods, are well established in the Hailey area. He then worked for a year as an Emergency Department physician in Missoula, Montana before starting his Family Medicine Practice in Hailey, Idaho in 1981. He completed his residency in Family Medicine at the University of Arizona Health Sciences Center in Tucson, Arizona. However, his need to help others drove him to attend Medical School, which he did in Rochester, New York. Louis with a Bachelor’s Degree in Biology. He graduated from Washington University in St. Richard Paris was born in Minnesota but grew up in North Dakota. Since then he flies, or drives, the 2+ hours to Challis twice a month to see his ob/gyn patients, complete administrative duties and confer with other Challis healthcare providers about local patients.ĭr. Paris was named Medical Director for the Challis Clinic in 1999. Paris always arrives at the Clinic with a smile on his face and a spring in his step. A familiar and welcoming sight in Challis, Dr. PMID:30758946.“Neither snow nor rain nor heat nor gloom of night stays these couriers from the swift completion of their appointed rounds.” Although originally seen on a wall of the General Post Office in New York City, this motto is uniquely appropriate for Challis Area Health Cares Medical Director, Dr. Obeng S, Jali A, Zheng Y, Wang H, Schwienteck KL*, Chen C, Stevens DL, Akbarali H, Dewey WL, Banks ML, Liu-Chen LY, Selley DE, Zhang Y (2019) Characterization of 17-Cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-(indole-7-carboxamido)morphinan (NAN) as a novel opioid receptor modulator for opioid use disorder treatment. PMC6476319.įaunce KE*, Banks ML (2019) Effects of repeated kappa-opioid agonist U-50488 treatment and subsequent termination on intracranial self-stimulation in male and female rats. Schwienteck KL*, Faunce KE*, Rice KC, Obeng S, Zhang Y, Blough BE, Grim TW, Negus SS, Banks ML (2019) Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats. Townsend EA*, Negus SS, Caine SB, Thomsen M, Banks ML (2019) Sex differences in opioid reinforcement under a fentanyl vs. food choice and blocks expression of opioid-withdrawal induced increases in fentanyl choice in rats. Townsend EA*, Blake S, Faunce KE*, Hwang CS, Natori Y, Zhou B, Bremer PT, Janda KD, Banks ML (2019) Conjugate vaccine produces long-lasting attenuation of fentanyl vs. PMC5651207īanks ML, Negus SS (2017) Insights from preclinical choice models on treating drug addiction. Negus SS, Banks ML (2018) Modulation of drug choice by chronic drug exposure and withdrawal in rhesus monkeys: Implications for negative reinforcement as a driver of addiction and target for medications development. Mukhara D, Banks ML, Neigh GN (2018) Stress as a risk factor for substance use disorders: A mini-review of molecular mediators. ![]() PMC6462013.ĭiester CM*, Banks ML, Neigh GN, Negus SS (2019) Experimental design and analysis for consideration of sex as a biological variable. Reviews/Perspectives: (*denotes graduate student, postdoctoral fellow, technician as author)īanks ML, Townsend EA*, Negus SS (2019) Testing the 10 most wanted: a preclinical algorithm to screen candidate opioid use disorder medications. Ultimately the goal of our preclinical studies is to translate our results in developing efficacious clinical treatment strategies for drug addiction.įor a complete list of publications listed in PubMed Our working hypothesis is that an effective treatment strategy, both pharmacological and behavioral, should facilitate reallocation of behavior away from drug choice toward choice of competing, alternative reinforcers. The overall theme of my research centers on understanding the neurobehavioral mechanisms of drug choice over other competing non-drug reinforcers. Use of choice procedures in preclinical models of drug abuse.Medications development for opioid and psychostimulant addiction.Ohio Northern University, Pharm.D., 2003.Department: Department of Pharmacology and ToxicologyĮmail: Robert Blackwell Smith Building, Room 760A
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |